LianBio (LIAN) Files For up to $100M IPO

LianBio (NASDAQ: LIAN) files for up to $100,000,000 IPO.

The company describes itself as: "We are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. We have purposefully designed our organization to successfully execute on our vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. We are establishing an international infrastructure to position ourselves as a partner of choice with a platform to provide access to our target markets."

Goldman Sachs & Co. LLC, Jefferies and BofA Securities will serve as lead underwriters.

You May Also Be Interested In